2 news items
Apellis Pharmaceuticals And Sobi Announce Positive One-Year Results From Phase 2 NOBLE Study Of Pegcetacoplan For Post-Transplant Recurrence Of C3 Glomerulopathy (C3G) And IC-MPGN
APLS
24 May 24
Rapid reduction in disease activity seen at 12 weeks was sustained at one year55% of patients showed zero C3c staining
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
APLS
24 May 24
reduction in disease activity seen at 12 weeks was sustained at one year
- Prev
- 1
- Next